Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
3Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Telomir Pharmaceuticals, Inc. (TELO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
3Distinct source URLs
8High confidence
0.823Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Telomir Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
MIRALOGX
MIRALOGX
92%
The MIRALOGX License Agreement provides for the payment to MIRALOGX of an 8% royalty (payable quarterly) on our net sales of Licensed Products by us or our sublicensees
TELI-PHARMACEUTICALS-INC
TELI-PHARMACEUTICALS-INC
92%
At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Company’s common stock, no par value issued to TELI’s former shareholders
BAYSHORE-TRUST
BAYSHORE-TRUST
90%
As a condition to closing, Bayshore Trust, a shareholder of TELI, contributed $1 million at closing to the Company
Telomir Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
of cash, primarily due to a net loss of $13.1 million, a $0.10 million net increase in accounts payable, accrued expenses and prepaid expenses, offset by $1.6 million in amortization of debt issuance…
MIRALOGX-LLC
MIRALOGX-LLC
62%
e Licensor goes bankrupt, TELI could lose its rights to Telomir-1 and all of such rights would revert back to the Licensor. Further, Licensor will control the process of applying for and obtaining an…
TELI-PHARMACEUTICALS-INC
TELI-PHARMACEUTICALS-INC
62%
believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of…
Telomir Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TELO-DEBT-12935
Warrants outstanding: 7
90%
xbrl warrant detail from xbrl 2024-12-31.
TELO-DEBT
Debt stack $202,869
90%
Market cache reports total debt of $202,869.
TELO-DEBT-12936
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
Telomir Pharmaceuticals, Inc. Acquisitions
Acquired Entity
Name
Confidence
Evidence
TELO-ACQ-0001493152-26-018867
Telomir Pharmaceuticals, Inc. issued 34,389,710 restricted shares to acquire TELI Pharmaceutical...
85%
Telomir Pharmaceuticals, Inc. issued 34,389,710 restricted shares to acquire TELI Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
TELO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 30 tracked holders.
Telomir Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
